Angiochem Initiates Phase 2 Clinical Study ...

Options


http://www.marketwatch.com/story/angiochem-initiates-phase-2-clinical-study-for-lead-drug-candidate-ang1005-in-her2-breast-cancer-with-brain-metastases-2014-05-30

Angiochem Initiates Phase 2 Clinical Study for Lead Drug Candidate,       ANG1005, in HER2+ Breast Cancer with Brain Metastases

Novel Peptide Drug Conjugate to Target HER2+ Breast Cancer Patients       with Progressive or Recurrent Brain Metastases, a Cancer with High Unmet       Medical Need

 

Comments

Categories